Prognostic and biological significance of survivin expression in patients with diffuse large B-cell lymphoma treated with rituximab-CHOP therapy

[1]  W. Choi,et al.  Evaluation of NF-κB subunit expression and signaling pathway activation demonstrates that p52 expression confers better outcome in germinal center B-cell-like diffuse large B-cell lymphoma in association with CD30 and BCL2 functions , 2015, Modern Pathology.

[2]  W. Choi,et al.  Prognostic impact of c-Rel nuclear expression and REL amplification and crosstalk between c-Rel and the p53 pathway in diffuse large B-cell lymphoma , 2015, Oncotarget.

[3]  K. Young,et al.  Genetic lesions in diffuse large B-cell lymphomas. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[4]  W. Choi,et al.  Age cutoff for Epstein-Barr virus-positive diffuse large B-cell lymphoma–is it necessary? , 2015, OncoTarget.

[5]  Rajen Dinesh Shah,et al.  Diffuse large B-cell lymphoma classification system that associates normal B-cell subset phenotypes with prognosis. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  W. Choi,et al.  Dysregulated CXCR4 expression promotes lymphoma cell survival and independently predicts disease progression in germinal center B-cell-like diffuse large B-cell lymphoma , 2015, Oncotarget.

[7]  T. Witzig,et al.  Prognostic factors for diffuse large B-cell lymphoma in the R(X)CHOP era. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[8]  W. Choi,et al.  Clinical Implications of Phosphorylated STAT3 Expression in De Novo Diffuse Large B-cell Lymphoma , 2014, Clinical Cancer Research.

[9]  M. Ciesielski,et al.  Challenges in the development of a survivin vaccine (SurVaxM) for malignant glioma , 2014, Expert review of vaccines.

[10]  S. Kuromitsu,et al.  Combination of YM155, a Survivin Suppressant, with Bendamustine and Rituximab: A New Combination Therapy to Treat Relapsed/Refractory Diffuse Large B-cell Lymphoma , 2014, Clinical Cancer Research.

[11]  W. Choi,et al.  MDM2 phenotypic and genotypic profiling, respective to TP53 genetic status, in diffuse large B-cell lymphoma patients treated with rituximab-CHOP immunochemotherapy: a report from the International DLBCL Rituximab-CHOP Consortium Program. , 2013, Blood.

[12]  N. Kaneko,et al.  Combination of YM155, a survivin suppressant with a STAT3 inhibitor: a new strategy to treat diffuse large B-cell lymphoma. , 2013, Leukemia research.

[13]  C. Tzeng,et al.  Comparison of prognostic models for patients with diffuse large B-cell lymphoma in the rituximab era , 2013, Annals of Hematology.

[14]  W. Choi,et al.  MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program. , 2013, Blood.

[15]  Mohita Upadhyay,et al.  The Warburg effect: insights from the past decade. , 2013, Pharmacology & therapeutics.

[16]  W. Choi,et al.  Patients with diffuse large B-cell lymphoma of germinal center origin with BCL2 translocations have poor outcome, irrespective of MYC status: a report from an International DLBCL rituximab-CHOP Consortium Program Study , 2013, Haematologica.

[17]  K. Hirata,et al.  Immunotherapeutic benefit of α‐interferon (IFNα) in survivin2B‐derived peptide vaccination for advanced pancreatic cancer patients , 2013, Cancer science.

[18]  E. Riedmann.  Ovarian cancer vaccine candidate DPX-Survivac: positive interim results from phase 1. , 2012, Human vaccines & immunotherapeutics.

[19]  W. Choi,et al.  Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study. , 2012, Blood.

[20]  K. Dybkær,et al.  Comprehensive gene expression profiling and immunohistochemical studies support application of immunophenotypic algorithm for molecular subtype classification in diffuse large B-cell lymphoma: a report from the International DLBCL Rituximab-CHOP Consortium Program Study , 2012, Leukemia.

[21]  J. Vose,et al.  A phase II study of the survivin suppressant YM155 in patients with refractory diffuse large B‐cell lymphoma , 2012, Cancer.

[22]  T. Martinović,et al.  Survivin expression in patients with newly diagnosed nodal diffuse large B cell lymphoma (DLBCL) , 2012, Medical Oncology.

[23]  L. Ellis,et al.  Class I Histone Deacetylase Inhibitor Entinostat Suppresses Regulatory T Cells and Enhances Immunotherapies in Renal and Prostate Cancer Models , 2012, PloS one.

[24]  J. Friedberg.  Relapsed/refractory diffuse large B-cell lymphoma. , 2011, Hematology. American Society of Hematology. Education Program.

[25]  A. López-Guillermo,et al.  CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group. , 2011, The Lancet. Oncology.

[26]  Masamichi Mori,et al.  Antitumor effects of YM155, a novel survivin suppressant, against human aggressive non-Hodgkin lymphoma. , 2011, Leukemia research.

[27]  K. Hirata,et al.  Immunogenic enhancement and clinical effect by type‐I interferon of anti‐apoptotic protein, survivin‐derived peptide vaccine, in advanced colorectal cancer patients , 2011, Cancer science.

[28]  G. Specchia,et al.  High Ki67 Index and Bulky Disease Remain Significant Adverse Prognostic Factors in Patients with Diffuse Large B Cell Lymphoma before and after the Introduction of Rituximab , 2011, Acta Haematologica.

[29]  M. Sasamata,et al.  Broad spectrum and potent antitumor activities of YM155, a novel small‐molecule survivin suppressant, in a wide variety of human cancer cell lines and xenograft models , 2011, Cancer science.

[30]  A. Yamaguchi,et al.  Phase I clinical trial of survivin‐derived peptide vaccine therapy for patients with advanced or recurrent oral cancer , 2011, Cancer science.

[31]  B. Coiffier,et al.  Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte. , 2010, Blood.

[32]  M. P. Holloway,et al.  Acetylation Directs Survivin Nuclear Localization to Repress STAT3 Oncogenic Activity* , 2010, The Journal of Biological Chemistry.

[33]  M. Ahluwalia,et al.  Antitumor cytotoxic T-cell response induced by a survivin peptide mimic , 2010, Cancer Immunology, Immunotherapy.

[34]  Youn Wha Kim,et al.  Prognostic significance of pSTAT3 and Survivin expression in diffuse large B‐cell lymphoma , 2010 .

[35]  R. Gascoyne,et al.  MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy. , 2009, Blood.

[36]  K. Ohshima,et al.  Prognostic impact of immunohistochemical biomarkers in diffuse large B‐cell lymphoma in the rituximab era , 2009, Cancer science.

[37]  Š. Pospíšilová,et al.  miR-34a, miR-29c and miR-17-5p are downregulated in CLL patients with TP53 abnormalities , 2009, Leukemia.

[38]  D. Sabatini,et al.  Cancer Cell Metabolism: Warburg and Beyond , 2008, Cell.

[39]  K. Hirata,et al.  Clinical and immunological evaluation of anti-apoptosis protein, survivin-derived peptide vaccine in phase I clinical study for patients with advanced or recurrent breast cancer , 2008, Journal of Translational Medicine.

[40]  M. Tan,et al.  Prognostic factors in patients with diffuse large B cell lymphoma: Before and after the introduction of rituximab , 2008, Leukemia & lymphoma.

[41]  N. Shinton.  WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues , 2007 .

[42]  D. Vertommen,et al.  Molecular Identification of Mammalian Phosphopentomutase and Glucose-1,6-bisphosphate Synthase, Two Members of the α-D-Phosphohexomutase Family* , 2007, Journal of Biological Chemistry.

[43]  W. Mann,et al.  Nuclear and cytoplasmic survivin: molecular mechanism, prognostic, and therapeutic potential. , 2007, Cancer research.

[44]  U. Klein,et al.  Structure of a Survivin–Borealin–INCENP Core Complex Reveals How Chromosomal Passengers Travel Together , 2007, Cell.

[45]  A. Ng,et al.  Diffuse large B-cell lymphoma. , 2007, Seminars in radiation oncology.

[46]  D. Altieri.  The case for survivin as a regulator of microtubule dynamics and cell-death decisions. , 2006, Current opinion in cell biology.

[47]  Richard Simon,et al.  Molecular diagnosis of Burkitt's lymphoma. , 2006, The New England journal of medicine.

[48]  A. López-Guillermo,et al.  CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. , 2006, The Lancet. Oncology.

[49]  S. Eschrich,et al.  Persistent Activation of Stat3 Signaling Induces Survivin Gene Expression and Confers Resistance to Apoptosis in Human Breast Cancer Cells , 2006, Clinical Cancer Research.

[50]  D. Tan,et al.  Nuclear or cytoplasmic expression of survivin: What is the significance? , 2005, International journal of cancer.

[51]  Chaohong Sun,et al.  Solution structure of human survivin and its binding interface with Smac/Diablo. , 2005, Biochemistry.

[52]  A. Schimmer.  Inhibitor of Apoptosis Proteins: Translating Basic Knowledge into Clinical Practice , 2004, Cancer Research.

[53]  D. Altieri,et al.  Mitochondrial survivin inhibits apoptosis and promotes tumorigenesis. , 2004, The Journal of clinical investigation.

[54]  K. Hirata,et al.  Phase I clinical study of anti-apoptosis protein, survivin-derived peptide vaccine therapy for patients with advanced or recurrent colorectal cancer , 2004, Journal of Translational Medicine.

[55]  W. Sessa,et al.  Regulation of survivin function by Hsp90 , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[56]  John Calvin Reed,et al.  HBXIP functions as a cofactor of survivin in apoptosis suppression , 2003, The EMBO journal.

[57]  T. Speed,et al.  Summaries of Affymetrix GeneChip probe level data. , 2003, Nucleic acids research.

[58]  G. Feldman,et al.  Inhibition of STAT3 signaling induces apoptosis and decreases survivin expression in primary effusion lymphoma. , 2003, Blood.

[59]  W. R. Bishop,et al.  Human survivin is negatively regulated by wild-type p53 and participates in p53-dependent apoptotic pathway , 2002, Oncogene.

[60]  B. E. C. Oiffier,et al.  CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell Lymphoma , 2002 .

[61]  J. Eriksson,et al.  Human inhibitor of apoptosis protein (IAP) survivin participates in regulation of chromosome segregation and mitotic exit , 2001, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[62]  W. Earnshaw,et al.  Chromosomal passengers and the (aurora) ABCs of mitosis. , 2001, Trends in cell biology.

[63]  Hui Zhang,et al.  Regulation of apoptosis at cell division by p34cdc2 phosphorylation of survivin. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[64]  D. Vaux,et al.  Survivin and the inner centromere protein INCENP show similar cell-cycle localization and gene knockout phenotype , 2000, Current Biology.

[65]  K. Inokuchi,et al.  Disturbed expression of the anti-apoptosis gene, survivin, and EPR-1 in hematological malignancies. , 2000, Leukemia research : a Forum for Studies on Leukemia and Normal Hemopoiesis.

[66]  F. Sigaux,et al.  Expression and prognostic significance of survivin in de novo acute myeloid leukaemia , 2000, British journal of haematology.

[67]  J Diebold,et al.  Prognostic significance of survivin expression in diffuse large B-cell lymphomas. , 2000, Blood.

[68]  Ash A. Alizadeh,et al.  Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling , 2000, Nature.

[69]  R. Weiss,et al.  Tumor content of the antiapoptosis molecule survivin and recurrence of bladder cancer. , 1999, New England Journal of Medicine.

[70]  E. Felip,et al.  A novel anti-apoptosis gene: Re-expression of survivin messenger RNA as a prognosis marker in non-small-cell lung cancers. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[71]  Fengzhi Li,et al.  Control of apoptosis and mitotic spindle checkpoint by survivin , 1998, Nature.

[72]  D. Altieri,et al.  Inhibition of apoptosis by survivin predicts shorter survival rates in colorectal cancer. , 1998, Cancer research.

[73]  D. Altieri,et al.  Anti-apoptosis gene, survivin, and prognosis of neuroblastoma , 1998, The Lancet.

[74]  D. Altieri,et al.  A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma , 1997, Nature Medicine.

[75]  Emili Montserrat,et al.  A predictive model for aggressive non-Hodgkin's lymphoma. , 1993, The New England journal of medicine.

[76]  T M Grogan,et al.  Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. , 1993, The New England journal of medicine.

[77]  J. Bouma,et al.  CERVICAL CARCINOMA IN YOUNGER PATIENTS , 1983, The Lancet.

[78]  V. Devita,et al.  ADVANCED DIFFUSE HISTIOCYTIC LYMPHOMA, A POTENTIALLY CURABLE DISEASE RESULTS WITH COMBINATION CHEMOTHERAPY , 1975, The Lancet.

[79]  W. Choi,et al.  Rearrangements of MYC gene facilitate risk stratification in diffuse large B-cell lymphoma patients treated with rituximab-CHOP , 2014, Modern Pathology.

[80]  B. Labar,et al.  Prognostic Significance of Survivin and Caspase-3 Immunohistochemical Expression in Patients with Diffuse Large B-cell Lymphoma Treated with Rituximab and CHOP , 2010, Pathology & Oncology Research.

[81]  P. Sullivan,et al.  Genetic variation in Transaldolase 1 and risk of squamous cell carcinoma of the head and neck. , 2008, Cancer detection and prevention.

[82]  B. Angus,et al.  A new subtype-specific monoclonal antibody for IAP-survivin identifies high-risk patients with diffuse large B-cell lymphoma and improves the prognostic value of bcl-2. , 2008, International journal of oncology.

[83]  里見 井手之上.  A potent immunogenic general cancer vaccine that targets survivin, an inhibitor of apoptosis proteins , 2004 .

[84]  D. Altieri.  Validating survivin as a cancer therapeutic target , 2003, Nature Reviews Cancer.

[85]  田中 慶太朗,et al.  Expression of survivin and its relationship to loss of apoptosis in breast carcinomas , 2000 .

[86]  篠澤 功.  Disturbed expression of the anti-apoptosis gene, Survivin, and EPR-1 in hematological malignancies , 2000 .